Liposarcoma is a type of tumour that arises from fat tissues in thighs, legs, abdomen, and retroperitoneum. Liposarcoma is also considered as malignant tumour because it spread to surrounding organs. According to the World Health Organization, liposarcoma is characterized into five types including, myxoid, well differentiated, dedifferentiated, round cell, and pleomorphic. Liposarcoma is generally observed as painless enlarged mass. It affects men and women equally. Well differentiated liposarcoma are non-metastasizing tumour that is rarely symptomatic and grows slowly. Myxoid liposarcoma affects deep soft tissues of extremities and is mostly observed in thigh muscles. Pleomorphic liposarcoma affects mostly in lower extremities. Novartis AG is in the process of developing HDM-201 as a p53-Mdm2 interaction inhibitor for the treatment of liposarcoma. Karyopharm Therapeutics, Inc. is in the process of developing selinexor as a exportin-1 protein inhibitor for the treatment of liposarcoma. Some of the companies having a pipeline of liposarcoma include Novartis AG, Karyopharm Therapeutics, Inc., Sanofi SA, and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.